Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Contract Biomanufacturing Services Market Forecasts to 2025 - Research and Markets

Research and Markets
Posted on: 24 Aug 17

The "Contract Biomanufacturing Services Global Market - Forecast to 2025" report has been added to Research and Markets' offering.

The contract biomanufacturing global market is expected to grow at double digit CAGR to reach $36.6 billion by 2025.

There is a continued growth of biopharmaceutical market which is expected to nearly double in next 10 years. This will be a result of continued new product approvals, expansion of indications for current products which include less-developed countries becoming more affluent and increased drug demand of the aging population in the U.S. and other major pharmaceutical markets.

Aging populations are at a high risk of developing chronic diseases such as cancer and arthritis and these diseases are being precisely targeted using biopharmaceuticals. Many blockbuster drugs losing their exclusivity are also giving room for many biosimilar (and bio-betters) companies to enter into the world's biopharmaceuticals market subsequently attracting many CROs, CDMOs, and CMOs to enter into the picture.

Contract manufacturing market was estimated region wise with segmental revenues for various end user groups such as diagnostics, research reagents and therapeutics. Total available manufacturing capacity was estimated with distinction between GMP vs. non-GMP, in-house vs. CMOs and clinical vs. commercial contract manufacturing. Key developments such as collaborations, capacity expansions and acquisitions were reported and analyzed.

Key Topics Covered:

1 Biologics Contract Manufacturing Global Market

1.1 Executive Summary

2 Market Analysis

2.1 Factors Influencing Market

2.1.1 Drivers and Opportunities Globalization of Outsourcing for Biomanufacturing Increased Funding from Private Investors and Government for Development of Cmos Emergence of Single Use Bioreactors Increasing Biologics Approvals in the Past Year Successful Collaboration and Low Cost for Outsourcing

2.1.2 Restraints and Threats High Requirement for Capital Investments Restraining Many Cmos to Enter the Biologics Space Risk of Product Contamination & Maintaining High Productivity Entry of Large Pharmaceutical Company With Exess Capacity Into the Cmo Market Stringent Regulations and Mandatory Requirement of Cgmp Certifications

3 Contract Biomanufacturing Services

3.1 Introduction

3.2 Contract Biomanufacturing, by Process

3.3 Contract Biomanufacturing Global Market, by End Users

3.4 Contract Biomanufacturing Global Market, by Region

3.5 Competitive Landscape

3.6 Company Developments

4 Company Profiles

4.1 Abzena Plc

4.2 Albany Molecular Research Inc

4.3 Asahi Glass Co. Ltd.

4.4 Boehringer Ingelheim

4.5 Catalent Inc.

4.6 Charles River Laboratories

4.7 Fujifilm Holdings Corporation

4.8 Horizon Discovery Group, Plc

4.9 Innovent Biologics

4.10 Jhl Biotech Inc.

4.11 Lonza Group

4.12 Merck Kgaa

4.13 Patheon N.V.

4.14 Proteogenix

4.15 Rentschler Biotechnologie Gmbh

4.16 Selexis Sa

4.17 Syngene International

4.18 Wuxi Apptec

For more information about this report visit

View source version on

Business Wire

Last updated on: 24/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.